Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

InspireMD, Inc. NSPR

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.0M
▲ 28.1% YoY
$-48.8M
$-36.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Our first product, the CGuard Carotid Embolic Prevention System (“CGuard EPS”), integrates a self-expanding nitinol stent with a MicroNet mesh sleeve as a single device for carotid artery revascularization. CGuard Prime received premarket approval (“PMA”) by the U.S. Food and Drug Administration (“FDA”) on June 23, 2025, and is marketed exclusively in the United States through our direct salesforce. We were organized in the State of Delaware on February 29, 2008. In October 2024, we established our global headquarters in Miami, Florida to support the U.S. launch and commercialization of CGuard Prime.

Written from the business description in InspireMD, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.

Growth

USD 9.0M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.0 · Net income -48.8
4M8M-20M-40M
200920122016201920222025
Compound annual growth
+20.2%
+29.3%
+14.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +29.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−543 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -552.6% · Net -543.3%
-500%
200920172025
ROE
FY2025 · ROE -106.9%
-100%-200%
200920172025
Three returns, three denominators.

Each USD of equity lost 107 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -36.8
-15M-30M
200920172025
Net buybacks $M Dividends $M
FY2011 · Dividends · · Net buybacks -1.5
-1M-2M
2011

Total assetsUSD 69.4M
EquityUSD 55.2M
CashUSD 8.9M
Current ratio5.74×

Equity funds 80% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NSPR, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.0◌0.00.00.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.76−0.76−0.82−2.35−2.03−6.97−4.80−16.67−34.98−207.72−55.85−7.09−1.39−1.04−0.07−0.06
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−106.9−84.7−70.0−72.6−65.3−120.2−141.9−126.0−249.2———−272.3———
Shares out B0.040.030.020.010.010.050.000.040.000.000.010.040.030.070.05◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 76 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image